Such findings were also reflected in the clinical setting where increased plasma levels of TGF-β correlated with colorectal cancer progression, and an increase in immunostaining of TGF-β has been implicated with metastasis in prostate, breast and colon cancer patients (88–91). Here, TGFB1 is linked to colorectal cancer.